Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society

Monoclonal antibodies against the calcitonin gene-related peptide (CGRP) receptor (Erenumab) or against CGRP (Eptinezumab, Fremanezumab, Galcanezumab) are new substances for the preventive treatment of migraine. They represent an extension of the therapeutic options, which already exist in migraine...

Descripción completa

Detalles Bibliográficos
Autores principales: Diener, Hans-Christoph, Förderreuther, Stefanie, Gaul, Charly, Giese, Florian, Hamann, Till, Holle-Lee, Dagny, Jürgens, Tim P., Kamm, Katharina, Kraya, Torsten, Lampl, Christian, May, Arne, Reuter, Uwe, Scheffler, Armin, Tfelt-Hansen, Peer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Guideline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650107/
https://www.ncbi.nlm.nih.gov/pubmed/33324917
http://dx.doi.org/10.1186/s42466-020-00057-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7650107/
https://www.ncbi.nlm.nih.gov/pubmed/33324917
http://dx.doi.org/10.1186/s42466-020-00057-1

Ejemplares similares